Positives

• In the CALVID-1 phase 2 trial, vidofludimus calcium showed antiviral activity against SARS-CoV-2 alongside its known anti-inflammatory effect via DHODH inhibition PMC.
  
  
• In the EMPhASIS multiple sclerosis trial, both 30 mg and 45 mg doses significantly reduced MRI lesions over 24 weeks with a favorable tolerability profile, supporting safe chronic dosing Neurology.
  
  

Negatives

• No dedicated Long COVID outcomes have been published; existing COVID data come from the acute hospitalized CALVID-1 cohort rather than PASC patients Imux.
  
  

Hurdles & Side Effects

• Vidofludimus calcium remains an investigational drug not approved by the FDA or EMA for any indication, so access requires enrollment in an active Immunic-sponsored trial Imux.